2019
Emergency department visits for prescription and synthetic opioid overdoses among patients with cancer.
Jairam V, Yang D, Yu J, Park H. Emergency department visits for prescription and synthetic opioid overdoses among patients with cancer. Journal Of Clinical Oncology 2019, 37: 6579-6579. DOI: 10.1200/jco.2019.37.15_suppl.6579.Peer-Reviewed Original ResearchED visitsOpioid overdoseEmergency departmentHigh riskOverdose ratesCervical cancerSynthetic opioidsUtilization Project Nationwide Emergency Department SampleNationwide Emergency Department SampleNon-cancer patientsEnd Results ProgramEmergency Department SampleIntrahepatic bile ductsPrimary cancer siteSynthetic opioid overdoseDiagnosis of cancerRespiratory intubationMetastatic diseaseHospital admissionOpioid dependencePrimary cancerBile ductResults ProgramCancer patientsCommon cancer
2017
Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance
Mahal A, Mahal B, Nguyen P, Yu J. Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer 2017, 124: 752-759. PMID: 29084350, DOI: 10.1002/cncr.31106.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityMetastatic diseaseCancer-specific mortalityProstate cancer outcomesOutcomes of patientsMedicaid insuranceEnd Results ProgramReceipt of therapyStage of diseaseAfrican American patientsInsurance statusPrivately insured cohortDefinitive treatmentProstate cancerLocalized CaPResults ProgramPrivate insuranceCAP outcomesCancer outcomesAmerican patientsPatientsProstateRacial disparitiesAssociated with raceAssociated with racial disparitiesOutcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance.
Mahal A, Mahal B, Nguyen P, Yu J. Outcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance. Journal Of Clinical Oncology 2017, 35: 198-198. DOI: 10.1200/jco.2017.35.6_suppl.198.Peer-Reviewed Original ResearchProstate cancer-specific mortalityHigh-risk prostate cancerProstate cancerTreatment of high-risk prostate cancerInsurance statusCompeting-risks regression modelsHigh-risk CaPPrivately insured menGray's competing-risks regression modelHigh-risk diseaseCancer-specific mortalityEnd Results ProgramMultivariate logistic regressionMetastatic diseaseNon-black menResults ProgramPrivate insuranceInsured menAfrican American menLogistic regressionMetSOutcomesCancerMenMore-than-additive effect